Literature DB >> 12771941

HBX causes cyclin D1 overexpression and development of breast cancer in transgenic animals that are heterozygous for p53.

Andreas Klein1, Eva Guhl, Yin-Jeh Tzeng, Jutta Fuhrhop, Massimo Levrero, Monika Graessmann, Adolf Graessmann.   

Abstract

Transgenic mice, which selectively express the WAP-HBX transgene in mammary gland epithelial cells (ME-cells), were established in order to elucidate the consequences of HBX gene expression on organ differentiation, cell death program and tumor development. Transgene expression was demonstrable by RT-PCR, Northern and Western blot analysis during pregnancy, lactation and after weaning. HBX synthesis neither affect mammary gland differentiation nor apoptosis in ME-cells. Although breast cancer formation was rare in WAP-HBX animals (<1%), WAP-HBX*p53+/- hybrid animals developed breast tumors at an increased rate (12/85) after a latency period of 8-18 months. We also show here for the first time that HBX can immortalize ME-cells generated from mammary gland tissue segments in a p53-independent fashion. HBX causes cyclin D1 gene overexpression during early pregnancy, and this is maintained in ME-cells isolated either from mammary gland or from breast tumors. Intranuclear cyclin D1 accumulation also occurs in the absence of external growth factors and the BrdU incorporation rate remains high under serum starvation conditions. Finally, both cyclin D1 induction and HBX mitotic activity are dependent on p38 and c-Jun N-terminal kinase, but not on MEK-1 kinase activity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12771941     DOI: 10.1038/sj.onc.1206539

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  20 in total

Review 1.  The enigmatic X gene of hepatitis B virus.

Authors:  Michael J Bouchard; Robert J Schneider
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

Review 2.  Viral manipulation of DNA repair and cell cycle checkpoints.

Authors:  Mira S Chaurushiya; Matthew D Weitzman
Journal:  DNA Repair (Amst)       Date:  2009-05-26

3.  Hepatitis B virus molecular biology and pathogenesis.

Authors:  R Jason Lamontagne; Sumedha Bagga; Michael J Bouchard
Journal:  Hepatoma Res       Date:  2016-07-01

Review 4.  Chronic hepatitis B in hepatocarcinogenesis.

Authors:  N H Park; I H Song; Y-H Chung
Journal:  Postgrad Med J       Date:  2006-08       Impact factor: 2.401

5.  Molecular Pathogenesis of Hepatitis-B-virus-associated Hepatocellular Carcinoma.

Authors:  Neung Hwa Park; Il Han Song; Young-Hwa Chung
Journal:  Gut Liver       Date:  2007-12-31       Impact factor: 4.519

6.  Involvement of nuclear factor of activated T cells 3 (NFAT3) in cyclin D1 induction by B[a]PDE or B[a]PDE and ionizing radiation in mouse epidermal Cl 41 cells.

Authors:  Jin Ding; Ronghe Zhang; Jingxia Li; Caifang Xue; Chuanshu Huang
Journal:  Mol Cell Biochem       Date:  2006-04-28       Impact factor: 3.396

7.  Gene expression profiling: cell cycle deregulation and aneuploidy do not cause breast cancer formation in WAP-SVT/t transgenic animals.

Authors:  Andreas Klein; Eva Guhl; Raphael Zollinger; Yin-Jeh Tzeng; Ralf Wessel; Michael Hummel; Monika Graessmann; Adolf Graessmann
Journal:  J Mol Med (Berl)       Date:  2005-01-21       Impact factor: 4.599

8.  c-Jun/AP-1 pathway-mediated cyclin D1 expression participates in low dose arsenite-induced transformation in mouse epidermal JB6 Cl41 cells.

Authors:  Dongyun Zhang; Jingxia Li; Jimin Gao; Chuanshu Huang
Journal:  Toxicol Appl Pharmacol       Date:  2008-11-14       Impact factor: 4.219

Review 9.  Hepatitis B Virus X and Regulation of Viral Gene Expression.

Authors:  Betty L Slagle; Michael J Bouchard
Journal:  Cold Spring Harb Perspect Med       Date:  2016-01-08       Impact factor: 6.915

10.  Distinctive pharmacological differences between liver cancer cell lines HepG2 and Hep3B.

Authors:  Guo-Hua Qiu; Xiaojin Xie; Fang Xu; Xiaohao Shi; Yue Wang; Linhong Deng
Journal:  Cytotechnology       Date:  2014-07-08       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.